Methylprednisolone can be used during pregnancy when the medical benefit outweighs the potential risk to the fetus, but it is not considered entirely risk-free. The FDA labeling requires providers to weigh benefits against “potential hazards to the mother and embryo or fetus” because adequate human reproduction studies have not been completed. In practice, many pregnant women do take this medication for conditions like severe nausea, lupus flares, and asthma exacerbations, typically under close medical supervision.
How Methylprednisolone Reaches the Fetus
Your placenta contains an enzyme that acts as a gatekeeper for corticosteroids, breaking down active drug into inactive forms before it reaches your baby. For related steroids like prednisolone, this enzyme reduces fetal exposure to roughly one-tenth of the mother’s blood level. However, methylprednisolone appears to be less effectively broken down by this placental enzyme, meaning a higher proportion may cross to the fetus compared to prednisolone or prednisone. This is one reason some providers prefer prednisone or prednisolone when a corticosteroid is needed during pregnancy, reserving methylprednisolone for situations where it offers a clear advantage.
First Trimester: The Cleft Lip Question
The most studied concern with corticosteroid use in early pregnancy is a possible small increase in the risk of cleft lip, with or without cleft palate. A 2000 meta-analysis of case-control studies found that first-trimester corticosteroid use was associated with roughly 3.4 times the odds of oral clefts. More recent, larger studies have found a smaller effect. The most current estimate from the National Birth Defects Prevention Study puts the odds ratio at about 1.6, which translates to the baseline risk rising from approximately 1.7 per 1,000 live births to 2.7 per 1,000 live births.
To put that in perspective, that means for every 1,000 babies exposed to corticosteroids in the first trimester, roughly one additional baby might be affected. The data is also conflicting because it is difficult to separate the effect of the medication from the effect of the underlying disease being treated. Still, when possible, many providers try to avoid systemic corticosteroids during the first trimester or use the lowest effective dose.
Risks With Longer or Higher Doses
Prolonged corticosteroid use during pregnancy has been linked to intrauterine growth restriction and lower birth weight. These effects appear to be dose-dependent, meaning short courses carry less risk than weeks or months of daily use. One large pooled analysis looking at gestational diabetes found that oral corticosteroid use during pregnancy raised the rate only slightly, from 7.4% to 9.5%, and the adjusted risk was essentially the same as in unexposed women. So a brief course is unlikely to trigger gestational diabetes on its own, though your provider may monitor blood sugar more closely if you need ongoing treatment.
For the baby, the main concern with high-dose or prolonged use late in pregnancy is adrenal suppression. Because methylprednisolone crosses the placenta more readily than some alternatives, it poses a somewhat higher risk of suppressing the baby’s own cortisol production. In a published case, a woman who took 64 to 96 mg of methylprednisolone daily from mid-pregnancy through delivery had a premature infant who developed adrenal insufficiency, showing up as low blood sugar and low sodium levels in the first days of life. This is rare, but newborns exposed to high doses in utero may need blood sugar and sodium monitoring after birth.
Conditions That May Justify Use
Several pregnancy-related and chronic conditions sometimes require corticosteroid treatment, and the benefit of controlling the disease often outweighs the medication’s risks. Severe hyperemesis gravidarum (intractable vomiting) is one example. A randomized controlled trial found that a short course of methylprednisolone was more effective than promethazine for stopping vomiting, with no patients in the methylprednisolone group requiring hospital readmission within two weeks, compared to five readmissions in the other group.
Autoimmune conditions like lupus, inflammatory bowel disease, and severe asthma sometimes flare during pregnancy and can threaten both mother and baby if left uncontrolled. Unmanaged lupus flares, for instance, raise the risk of preeclampsia, preterm birth, and pregnancy loss. In these situations, the risks of not treating typically exceed the risks of the medication itself.
How It Compares to Other Corticosteroids
Not all corticosteroids behave the same way during pregnancy. Prednisone and prednisolone are generally preferred for treating maternal conditions because the placental enzyme breaks them down more effectively, limiting how much reaches the baby. Methylprednisolone is less efficiently inactivated by that enzyme, so fetal exposure tends to be higher at equivalent doses.
On the other hand, betamethasone and dexamethasone are deliberately chosen when the goal is to reach the fetus, such as accelerating fetal lung maturation before a preterm delivery. These steroids largely bypass the placental enzyme. The standard protocol for fetal lung maturity involves two doses of betamethasone given 24 hours apart, recommended for women between 24 and 34 weeks of gestation who are at risk of delivering within seven days. This is a completely different clinical situation from using methylprednisolone to treat a maternal condition.
Breastfeeding After Methylprednisolone
If you’re taking methylprednisolone after delivery, the amount that passes into breast milk is low. At standard doses, the relative infant dose is about 0.5% of the mother’s weight-adjusted dose, well below the 10% threshold generally considered acceptable during breastfeeding. For routine oral doses, no special timing is needed.
High-dose intravenous pulses, such as the 1-gram infusions used for multiple sclerosis relapses, do temporarily spike milk levels. Waiting four hours after a high-dose infusion before nursing reduces the baby’s exposure to about 42% of their daily natural cortisol output. Waiting eight hours drops it to around 12%. For most mothers receiving pulse therapy, pumping and discarding milk for four hours after the infusion, then resuming nursing, is a practical approach that substantially limits infant exposure.